Tag Archives: National Cancer Institute

Pomalidomide for Multiple Myeloma – National Cancer Institute


Pomalidomide for Multiple Myeloma – National Cancer Institute.

 

Otto Kahler

Otto Kahler (Photo credit: Wikipedia)

 

 

 

Multiple myeloma
Classification and external resources
Plasmacytoma ultramini1.jpg

Micrograph of a plasmacytoma, the histologiccorrelate of multiple myeloma. H&E stain
ICD10 C90.0
ICD9 203.0
ICD-O: M9732/3
OMIM 254500
DiseasesDB 8628
MedlinePlus 000583
eMedicine med/1521
MeSH D009101

 

Pomalidomide
Pomalidomide2DACS.svg
Systematic (IUPAC) name
4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Clinical data
Trade names Imnovid, Pomalyst
Licence data EMA:LinkUS FDA:link
Pregnancy cat. (US)
Legal status POM (UK) -only (US)
Routes Oral
Pharmacokinetic data
Protein binding 12–44%
Metabolism Hepatic (mostly CYP1A2 andCYP3A4 mediated; some minor contributions by CYP2C19 andCYP2D6)
Half-life 7.5 hours
Excretion Urine (73%), faeces (15%)
Identifiers
CAS number 19171-19-8 Yes
ATC code L04AX06
PubChem CID 134780
ChemSpider 118785 
UNII D2UX06XLB5 
ChEMBL CHEMBL43452 
Chemical data
Formula C13H11N3O4 
Mol. mass 273.24 g/mol

 

 

 

 

Enhanced by Zemanta
Advertisements

Cancer Death Risk Greater for Men


Cancer Death Risk Greater for Men

US researchers say men diagnosed with cancer are more likely to die from the disease than women. They attribute the discrepancy in part to the fact that men are at greater risk of developing cancer than women, perhaps as a result of differences in exposure to carcinogens or hormonal or metabolic differences. According to the American Cancer Society, men have about a 1 in 2 chance of developing cancer, while women have just a 1 in 3 chance. In addition, men are more likely than women to have advanced disease by the time their cancer is detected. More… Discuss